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With advancing age, there is an increase in the complaints of a lack of a libido in women and erectile dys-
function in men. The efficacy of phosphodiesterase type 5 inhibitors, together with their minimal side effects
and ease of administration, revolutionized the treatment of erectile dysfunction. For women, testosterone
administration is the principal treatment for hypoactive sexual desire disorder. We sought to evaluate the use
of androgens in the treatment of a lack of libido in women, comparing two periods, i.e., before and after the
advent of the phosphodiesterase type 5 inhibitors. We also analyzed the risks and benefits of androgen
administration. We searched the Latin-American and Caribbean Health Sciences Literature, Cochrane Library,
Excerpta Medica, Scientific Electronic Library Online, and Medline (PubMed) databases using the search terms
disfunc¸a˜o sexual feminina/female sexual dysfunction, desejo sexual hipoativo/female hypoactive sexual desire
disorder, testosterona/testosterone, terapia androgeˆnica em mulheres/androgen therapy in women, and
sexualidade/sexuality as well as combinations thereof. We selected articles written in English, Portuguese, or
Spanish.
After the advent of phosphodiesterase type 5 inhibitors, there was a significant increase in the number of
studies aimed at evaluating the use of testosterone in women with hypoactive sexual desire disorder. However,
the risks and benefits of testosterone administration have yet to be clarified.
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& INTRODUCTION
Since 1930, testosterone has been used to treat various
gynecological problems such as uterine hemorrhage,
myoma, dysmenorrhea, chronic mastitis, malignant endo-
metrial tumors, and malignant breast tumors; the correla-
tion between testosterone and the female libido was first
reported by Loeser (in 1940) and was subsequently
confirmed by Greenblatt et al. (in 1942) and Salmon et al.
(in 1943) (1). However, the sexual response is multifactorial
and depends on psychological and social aspects; on the
effects of hormones such as estrogen, prolactin, progester-
one, and oxytocin; and on the effects of neurotransmitters
and neuropeptides, including nitric oxide, dopamine,
serotonin, and gamma-aminobutyric acid (1-10). Therefore,
it is difficult to determine the specific effects of testosterone
on female hypoactive sexual desire disorder (HSDD) (10).
In the last decade, increasing attention has been given
to the neurobiology of sexual function due to the high
prevalence of sexual difficulties in men and women as well
as the successful use of phosphodiesterase type 5 (PDE5)
inhibitors in the treatment of erectile dysfunction (2).
Androgen levels and sexual behavior in aging
women
A study conducted in the United States showed that
26.7% of all women of reproductive age and 54.2% of all
postmenopausal women complain of decreased libido (11).
In a study investigating the sexual life of the Brazilian
population, 5.8% of the women in the 18-25 year age bracket
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reported inhibited sexual desire, as did 8.6% of those in the
41-50 year age bracket, 15.25% of those in the 51-60 year age
bracket, and 19.9% of those over 60 years of age (12).
Dennerstein et al. (13) correlated sexual behavior and low
androgen production in aging women, concluding that the
decline in androgen production coincides with decreased
sexual motivation and fantasies. In contrast, the results of a
study of women in the 42-52 year age bracket varied by
ethnicity, abdominal obesity, physical activity, mood, and
smoking (14).
Studies investigating the correlation of appetite, sexual
arousal, and orgasm with measurements of total testoster-
one, free testosterone, androstenedione, and dehydroepian-
drosterone sulfate have yielded inconclusive results. In
those studies, it was impossible to determine a cut-off point
for androgen levels that would define and assist in the
diagnosis of female androgen insufficiency (1,15,16). In
contrast, the Study of Women’s Health Across the Nation
showed a correlation between increased complaints of
HSDD and decreased free testosterone levels but not
between decreased libido and total testosterone levels in
aging women (17).
In aging individuals, sexual behavior does not depend
solely on androgen levels. In addition to experiencing the
end of ovarian function, menopausal women undergo
physiological changes involving hormones and general
health. Depression, relationship changes or partner loss,
religious issues, and anxiety about the future are also
important. All of these elements are interconnected, and
social and emotional factors directly affect the somatic
factors (18).
Fluctuations in estrogen levels in perimenopausal women
can precipitate vasomotor symptoms, sleep disturbances,
and mastalgia, all of which impair the female sexual
response (19). The decline in serum estrogen levels after
menopause results in vaginal mucosal atrophy, vaginal
muscle atrophy, and reduced vaginal acidity, which
culminate in dyspareunia and can impair female sexual
desire (20). Therefore, the fact that the prevalence of HSDD
increases with age does not necessarily imply that the age-
related changes occur as a direct result of decreased
endogenous androgen levels.
Controversy regarding the diagnosis and treatment
of androgen deficiency in women
The 2002 Princeton consensus statement on the definition,
classification, and assessment of female androgen insuffi-
ciency (21) assessed the problems related to testosterone
insufficiency in women and found that the current studies
of those steroids are unsatisfactory, principally due to the
lack of sensitivity or reliability in the determination of the
normal levels. Therefore, the consensus statement recom-
mended that equilibrium dialysis methods be developed for
the adequate assessment of bioavailable testosterone in
women and, in the absence of an ideal method, the free
testosterone index be calculated for that purpose. Because
increased sex hormone-binding globulin levels can also
determine androgen insufficiency even in the presence of
normal total testosterone levels, they should be considered
for the calculation of bioavailable testosterone, and psycho-
social causes should be evaluated. Finally, the consensus
statement recommended that further studies be conducted,
given that the physiological mechanisms regulating andro-
gen homeostasis in women have yet to be clearly defined (21).
The 2006 Endocrine Society Clinical Practice Guidelines
on Androgen Therapy (22) recommended against the use
of androgen therapy in women. The recommendation was
based on the lack of the following: well-defined criteria for
the diagnosis of androgen insufficiency syndrome in
women; normative data on the serum levels of total and
free testosterone during the life cycle of women; data on the
safety of long-term androgen administration; a correlation
between sexual disorders and plasma testosterone levels;
and accurate and reliable assays for determining circulating
free and total testosterone. In addition, because clinical
studies are limited and there are no long-term studies, the
guidelines recommended that further studies be conducted
and that the use of testosterone for the treatment of female
HSDD be discouraged (22).
Traish et al. (23) disagreed with the 2006 Endocrine
Society Clinical Practice Guidelines on Androgen Therapy
(22) statement that there were no normative data on the
serum levels of total and free testosterone during the life
cycle of women, arguing that the panel ignored studies
such as those by Davison et al. (24) and Guay et al. (25),
which compared the levels of testosterone in healthy
premenopausal women complaining of HSDD and defined
the normal ranges for calculated free testosterone. In
Figure 1, Traish et al. (23) show and compare the results
obtained by Davison et al. (24) and Guay et al. (25). Traish
et al. (23) also argued that although Davis et al. (15) found
no correlation between total testosterone levels and sexual
dysfunction, they found a correlation between low dehy-
droepiandrosterone sulfate levels and female HSDD. Traish
et al. (23) concluded that the lack of reliability of the results
was solely due to the difficulty in accurately measuring free
testosterone levels in women. The authors also refuted the
argument that there was a lack of data on the safety of long-
term testosterone administration in women (22), stating that
various studies, such as those by Simon et al. (26), Buster
et al. (27), Davis et al. (28), and Braunstein et al. (29), had
shown only skin changes (oily skin, acne, and hirsutism)
and that the beneficial effects of testosterone use (increased
libido, sexual satisfaction, and quality of life) should be
given greater weight. The aforementioned findings show
that the use of testosterone for the treatment of female
HSDD remains controversial.
Mechanism of action of testosterone on the breasts
and cardiovascular system
Testosterone administration in women raises concerns
because of the effects of testosterone on breast tissue. The
relationship between male steroids and breast cancer is
complex because although epidemiological studies have
shown an association between elevated androgen levels and
the risk of breast tumors, experimental studies have shown
conflicting results depending on the cell lineage, the dose
and type of androgen, and the presence or absence of the
estrogen receptor on the cell. In addition, in vivo studies
involving rodents and rhesus monkeys suggest that andro-
gens limit estrogen-induced mitogenic activity and cancer
development in the breast (30).
Normal breast cell proliferation and breast tumor cell
proliferation are regulated by the balance between the
stimulating effects of estrogens and the inhibitory effects of
androgens. However, the levels of androgen and estrogen
required for these opposing mechanisms to occur have yet
to be well established (31). In addition, because testosterone
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undergoes aromatization and is converted to estradiol, it
can have opposing effects on breast tissue, meaning that it
can either inhibit or stimulate breast cell proliferation (32).
Regarding the effects of testosterone on the cardiovascu-
lar system, testosterone receptors are distributed through-
out the vasculature and are present on endothelial cells,
smooth muscle, and myocardial fibers. Testosterone acts
through three mechanisms. First, through a nongenomic
pathway, testosterone stimulates the production of nitric
oxide and inhibits the influx of calcium into the vascular
endothelium, inducing vasodilation (33). Second, through a
genomic pathway, testosterone acts through coregulatory
proteins, which act on the androgen receptor, stimulating or
restricting transcription; knowledge regarding this mechan-
ism remains limited (33). Third, it also acts through the
conversion of testosterone to estrogen via the aromatase
enzyme (34). In addition, by binding to its receptor in
ischemic conditions, testosterone can promote endothelial
cell apoptosis, which consequently induces increased plate-
let adhesiveness, thrombus formation, and atherogenesis
(35). Furthermore, primary atherosclerotic lesions are fatty
streaks that consist of T lymphocytes and lipid-laden
macrophages known as foam cells. Androgens increase
foam cell formation and therefore favor ischemic processes
(36).
& METHODS
This was a review of studies published from 1988-2012.
We searched the Medline (PubMed), Latin-American and
Caribbean Health Sciences Literature, Scientific Electronic
Library Online, Excerpta Medica, and Cochrane Library
databases using the search terms disfunc¸a˜o sexual femi-
nina/female sexual dysfunction, desejo sexual hipoativo/
female hypoactive sexual desire disorder, testosterona/
testosterone, terapia androgeˆnica em mulheres/androgen
therapy in women, and sexualidade/sexuality as well as
combinations thereof. We then selected articles written in
English, Portuguese, or Spanish that included middle-aged
human females or human females over 45 years of age. The
selected articles included randomized controlled trials,
literature reviews, and clinical trials.
A form was designed that contained the following items:
1) reviewer name; 2) article title; 3) author(s); 4) year of
publication; 5) source; 6) keywords; and 7) abstract. The
reviewers (i.e., the authors of the present study) indepen-
dently read and evaluated the article titles and abstracts
retrieved from the abovementioned databases to determine
whether the articles were suitable for inclusion in the
present review. Subsequently, the results were compared to
determine the concordance between the reviewers, with
discordant results being resolved by consensus. Duplicate
studies were excluded.
A total of 3880 articles were retrieved initially. By reading
the titles of the articles, we selected 531 potentially relevant
studies. After reading the respective abstracts, we selected
274 articles, all of which were read in their entirety. After
reading those articles in their entirety, we excluded 194. Of
those, 99 were studies examining the use of therapies other
than testosterone administration for the treatment of sexual
dysfunction in women, 61 were studies examining the use of
testosterone for purposes other than treating sexual dys-
function in women, and 34 were duplicate entries. A total of
80 articles remained and were classified by the type of
study. From among those, seven of the reviewed articles
showed results already described in our study and were
excluded. We selected 20 randomized studies for this
analysis (Table 1).
& RESULTS
Figure 2 shows the distribution of the articles over the last
22 years, by year of publication. As seen in Figure 2, the
number of studies began to increase in 2000, with peaks in
2003, 2005, and 2007.
On the basis of the results of the 20 selected studies, we
evaluated the effect of testosterone on the sexual response
and identified the risks of testosterone administration.
Figure 1 - Free testosterone levels in young women from two separate and independent studies. The calculated free testosterone values
are expressed in pmol/L. The mean age of the groups is shown in years (23). (Used with permission, Traish AM et al. Are the Endocrine
Society’s Clinical Practice Guidelines on Androgen Therapy in Women misguided? A commentary. J Sex Med. 2007;4(5):1223-34).
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Figure 3 shows the distribution of the randomized, placebo-
controlled trials by the year of publication. As shown in
Figure 3, the number of randomized, placebo-controlled trials
began to increase in 2000 and peaked in 2005, 2007, and 2008.
& DISCUSSION
Of the 20 randomized, placebo-controlled trials included
in the present review, 2 (10%) were published in the 1988-
1998 period and 18 (90%) were published in the 1999-2012
period, with peaks in 2005, 2007, and 2008 (Figure 3).
Therefore, after 1998, with the advent of PDE5 inhibitors,
there was a significant increase in the number of studies
examining the use of testosterone for the treatment of HSDD
in women.
Traish et al. (1) reviewed the studies published in 1930-
2000 that examined androgens, sexual function, and sexual
dysfunction in women. The number of studies examining
those issues peaked in the 1940s (when the effect of
testosterone on the libido was first observed) but subse-
quently dropped and began increasing again in the 1990-
2000 period. As shown in Figure 4, our findings corroborate
those of Traish et al. (1).
On the basis of our analysis of 20 randomized, placebo-
controlled trials, we can conclude that the male hormone
has a positive effect on sexual response, having been
reported to increase pleasure from masturbation (37), sexual
desire (26-28,38-44), the frequency of sexual activity
(26,27,38,40,45-48), sexual satisfaction (38,40-43,47,49-51),
and orgasm (28,38,45,46). One of the trials (52) began in
2008 and is still under way (with an expected trial duration
of approximately 5 years). These findings are consistent
with those of other studies showing increases in sexual
desire, the frequency of sexual activity, and sexual satisfac-
tion in women receiving androgen therapy (53-55).
Testosterone was found to have beneficial effects on libido
regardless of the route of administration (oral administra-
tion, transdermal administration, or implants). However,
in studies comparing two different doses of transdermal
testosterone (i.e., 150 mg and 300 mg) in terms of their
efficacy, testosterone was reported to have a beneficial effect
on sexual response only when a 300-mg dose was used
(40,45,46,56).
Of the 20 randomized, placebo-controlled trials included
in the present review, 2 examined the risk that androgen
administration poses to the cardiovascular system. El Hage
et al. (43) and Paula et al. (41) reported that the use of
testosterone increased the frequency of cardiac events.
Studies with the specific objective of evaluating the effect
of testosterone on the cardiovascular system showed a risk
of atherogenesis and thrombosis (35,36,57-59). In contrast,
Lellano et al. (60) reported that testosterone provided
cardiovascular protection, whereas other authors found
neither an increased cardiovascular risk nor cardiovascular
protection (61-63). Therefore, the effect of testosterone on
the cardiovascular system remains inconclusive.
The impact of testosterone on the breasts is an important
issue. The randomized trials shown in Table 1 do not allow
us to draw conclusions because they were all short-term
studies (the maximum duration being 24 weeks).
Of the 5 studies that analyzed the relationship between
the administration of testosterone and the risk of breast
cancer (64-68), only 1 showed a 2.5-fold increase in the risk
of breast cancer (a relative risk of 2.48) among womenA
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receiving estrogen in combination with testosterone (65),
whereas another showed that testosterone inhibited the cell
proliferation induced by the estrogen-progestogen combi-
nation (64). The remaining 3 studies showed that the
addition of testosterone did not induce the development
of breast cancer (66-68). On the basis of these conflicting
results, Kenemas et al. (69) stated that the long-term
administration of testosterone for the treatment of HSDD
in women merits further investigation.
One of the 20 randomized, placebo-controlled trials
shown in Table 1 examined the risk of liver disease in
women receiving androgens and showed no change in
hepatic enzymes (41). In the literature, this has been
reported only in cases in which the blood testosterone
levels increased to supraphysiological levels (26,45,70).
Other adverse effects of the use of testosterone in women,
such as hirsutism (55), deep voice, and an enlarged clitoris
(71), should not be neglected. However, the most common
adverse effects are acne and increased oiliness of the skin
and hair (55), which were also reported in 3 of the studies
shown in Table 1 (26,27,29). In addition, 10% of patients
receiving 1.25 mg/day or 2.5 mg/day of methyltestosterone
and 45% of those receiving 10 mg/day of the same were
reported to have experienced these side effects (72,73).
Masculinization is rare and is due to the administration of
high doses of androgens. Implants containing up to 300
mg/day of testosterone initially produce supraphysiological
blood peaks, although these are transient and do not induce
virilization (55).
Although the evidence shows that androgen administra-
tion positively affects the female sexual response, the impact
that the long-term administration of androgens has on the
physical health of women has yet to be clarified. No studies
in the literature have evaluated the use of testosterone for
the treatment of female HSDD or compared this treatment
modality before and after the advent of the PDE5 inhibitors.
In the present review, we found that in the years
preceding the commercial release of sildenafil, vardenafil,
and tadalafil, studies involving androgens were primarily
conducted with the objective of treating myomas, perime-
nopausal symptoms, breast cancer, dysmenorrhea, and
uterine hemorrhage and only showed that the male
hormone had an effect on the female sexual response. As
of 1998, the proportion of randomized studies investigating
the effect of testosterone on female HSDD had increased
from 10% to 90%, those studies having confirmed the
positive effect of testosterone on libido. That increase was
significant and suggests that the advent of PDE5 inhibitors
motivated further studies aimed at resolving complaints of
low libido in women with sexual dysfunction so that such
women became sexually adjusted to their partners. We
suggest that future research on other therapeutic approaches
for sexual dysfunctions in women, investigating whether a
correlation exists between the number of studies and the
discovery of PDE5 inhibitors as well as the risks and benefits
of such therapies, will be required.
Although there is no doubt about the positive effect of
testosterone on the female sexual response, all the rando-
mized trials examining this issue and published from 1998-
2012 were short-term studies (the maximum duration being
24 weeks). Therefore, it is impossible to draw definitive
conclusions regarding the side effects of the long-term
Figure 2 - Distribution of the selected articles over the 1988-2012 period by year of publication.
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administration of testosterone. However, it can be stated that
during the study periods, testosterone administration was
found to have no significant negative impact on the physical
health of the treated women. In addition, the controversy
regarding the diagnosis of female hypoandrogenism (this
controversy existed before the advent of PDE5 inhibitors)
remains unresolved. Therefore, although the number of
studies has increased in recent years, there is still no
consensus regarding the use of testosterone for the treatment
of HSDD in women.
Figure 3 - Randomized, placebo-controlled trials investigating the use of testosterone and hypoactive sexual desire disorder in women
and published in 1988-2012, distributed by year of publication.
Figure 4 - Number of studies examining androgens and sexual function or dysfunction in women and published in 1930-2000,
distributed by decade and separated into two distinct periods (1). (Used with permission, Traish AM et al. Testosterone therapy in
women with gynecological and sexual disorders: a triumph of clinical endocrinology from 1938 to 2008. J Sex Med. 2009;6(2):334-51).
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